The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
Open Access
- 24 February 2023
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 161, 114436
Abstract
No abstract availableKeywords
Funding Information
- Kurdistan University Of Medical Sciences (IR.MUK.REC.1401.324)
This publication has 104 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Viral and nonviral delivery systems for gene deliveryAdvanced Biomedical Research, 2012
- Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4Gene Therapy, 2011
- HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategyMolecular Cancer, 2011
- Species D Adenoviruses as Oncolytics against B-cell CancersClinical Cancer Research, 2011
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signalNature Immunology, 2009
- Yin–Yang of costimulation: crucial controls of immune tolerance and functionImmunological Reviews, 2009
- Tissue expression of PD-L1 mediates peripheral T cell toleranceJournal of Experimental Medicine, 2006
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003